Head-To-Head Contrast: Grifols, (GRFS) & Its Peers
Grifols, (NASDAQ: GRFS) is one of 93 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare Grifols, to related businesses based on the strength of its institutional ownership, analyst recommendations, profitability, dividends, valuation, risk and earnings.
This table compares Grifols, and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation & Earnings
This table compares Grifols, and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Grifols,||$5.13 billion||$1.45 billion||23.04|
|Grifols, Competitors||$223.74 million||$57.84 million||-0.73|
Grifols, has higher revenue and earnings than its rivals. Grifols, is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Grifols, pays an annual dividend of $0.28 per share and has a dividend yield of 1.4%. Grifols, pays out 31.1% of its earnings in the form of a dividend. As a group, “Biotechnology” companies pay a dividend yield of 1.4% and pay out 31.1% of their earnings in the form of a dividend.
This is a breakdown of recent ratings and recommmendations for Grifols, and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
As a group, “Biotechnology” companies have a potential upside of 53.39%. Given Grifols,’s rivals stronger consensus rating and higher possible upside, analysts clearly believe Grifols, has less favorable growth aspects than its rivals.
Risk and Volatility
Grifols, has a beta of 1, meaning that its share price has a similar volatility profile to the S&P 500.Comparatively, Grifols,’s rivals have a beta of 1.14, meaning that their average share price is 14% more volatile than the S&P 500.
Institutional and Insider Ownership
21.9% of Grifols, shares are held by institutional investors. Comparatively, 20.4% of shares of all “Biotechnology” companies are held by institutional investors. 20.1% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Grifols, beats its rivals on 7 of the 13 factors compared.
Grifols, S.A., a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics. It operates through four segments: Bioscience, Diagnostic, Hospital, and Raw Materials and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use, including the reception, analysis, quarantine, classification, fractionation, and purification of plasma; and sells and distributes end products. This segment offers plasma products, such as IVIG, Factor VIII, A1PI, and albumin; and intramuscular immunoglobulins, ATIII, Factor IX, and plasma thromboplastin components. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products comprising analytical instruments, reagents, software, and related products for use in clinical and blood bank laboratories. This segment serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital segment manufactures and installs products used by hospitals consisting of parenteral solutions, and enteral and parenteral nutritional fluids. The Raw Materials and Others segment sells intermediate biological products; and renders manufacturing services to third party companies. The company also offers engineering services. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves hospitals and clinics, group purchasing organizations, governments, and other distributors through sales representatives, marketing partners, and third-party distributors. Grifols, S.A. was founded in 1940 and is headquartered in Barcelona, Spain.
Receive News & Ratings for Grifols S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols S.A. and related companies with MarketBeat.com's FREE daily email newsletter.